LSLi Sheng

Li Sheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li Sheng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Can Jie Guo

    Division of Gastroenterology and Hepatology; Shanghai Institute of Digestive Disease; NHC Key Laboratory of Digestive Diseases; NHC Key Laboratory of Digestive Diseases; Renji Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China

    1 shared publication
  • Chiyi He

    Department of Gastroenterology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China

    1 shared publication
  • Dao-You Jin

    Department of Gastroenterology, Yijishan Hospital, Wuhu 241001, Anhui Province, China

    1 shared publication
  • Jing Hua

    State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Science, Guangxi Normal University, Guilin 541004, China

    1 shared publication
  • Lin Wang

    Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, Guangdong, China

    1 shared publication
  • Min Lian

    Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, NHC Key Laboratory of Digestive Diseases, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, China

    1 shared publication

Latest Publications

  • Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage peroxisome proliferator‐activated receptor gamma to prevent non‐alcoholic steatohepatitis progression in mice

    by Xi Xi Ni, Pei Xuan Ji, Yu Xin Chen, Xiao Yun Li, Li Sheng, Min Lian, Can Jie Guo, Jing Hua

    Background & Aims: Macrophages display remarkable plasticity and can interact with surrounding cells to affect hepatic immunity and tissue remodelling during the progression of liver diseases. Peroxisome proliferator‐activated receptor gamma (PPARγ) plays a critical role in macrophage maturation, polarization and metabolism. In this study, we investigated the role of PPARγ in macrophage–hepatic stellate cell (HSC) interaction during non‐alcoholic steatohepatitis (NASH) development.Methods: Wild‐type, Ppargfl/fl and PpargΔLyz2 mice were fed a methionine‐ and choline‐deficient (MCD) diet to induce NASH. Depletion of macrophages was performed using an injection of gadolinium chloride intraperitoneally. PPARγ‐overexpressing or PPARγ‐knockout macrophages were stimulated with saturated fatty acid (SFA) and cocultured with HSCs in a conditioned medium or the transwell coculture system.Results: Depletion of macrophages inhibited HSC activation and ameliorated NASH progression in MCD diet‐fed mice. Coculturing HSCs with macrophages or culturing HSCs in a macrophage‐conditioned medium‐facilitated HSC activation, and this effect was magnified when macrophages were metabolically activated by SFA. Moreover, the absence of PPARγ in macrophages enhanced metabolic activation, promoting the migration and activation of HSCs through IL‐1β and CCL2. In contrast, overexpression of PPARγ in macrophages obtained the opposite effects. In vivo, macrophage‐specific PPARγ knockout affected the phenotype of hepatic macrophages and HSCs, involving the MAPK and NLRP3/caspase‐1/IL‐1β signalling pathways. Infiltrating hepatic monocyte‐derived macrophages became the predominant macrophages in NASH liver, especially in PpargΔLyz2 mice, paralleling with aggravated inflammation and fibrosis.Conclusions: Regulating macrophage PPARγ affected the metabolic activation of macrophages and their interaction with HSCs. Macrophage‐specific PPARγ may be an attractive therapeutic target for protecting against NASH‐associated inflammation and fibrosis.


  • Open Access

    Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats

    by Sheng Li, Wan-Chun Wu, Chi-Yi He, Zhen Han, Dao-You Jin, Lin Wang

    Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats